4.4.1.11: methionine gamma-lyase
This is an abbreviated version!
For detailed information about methionine gamma-lyase, go to the full flat file.
Word Map on EC 4.4.1.11
-
4.4.1.11
-
lipase
-
monoacylglycerol
-
endocannabinoids
-
cannabinoids
-
lectin
-
putida
-
c-type
-
2-arachidonoylglycerol
-
pyridoxal
-
medicine
-
monoglyceride
-
orthotopic
-
galactose-type
-
galnac
-
selenomethionine
-
anandamide
-
freundii
-
2-arachidonoyl
-
citrobacter
-
alpha-ketobutyrate
-
methylselenol
-
meibomian
-
methionine-dependent
-
mercaptan
-
beta-lyase
-
5'-phosphate-dependent
-
dc-sign
-
s-substituted
-
synthesis
-
nutrition
-
environmental protection
-
analysis
-
drug development
- 4.4.1.11
- lipase
- monoacylglycerol
-
endocannabinoids
- cannabinoids
- lectin
- putida
-
c-type
- 2-arachidonoylglycerol
- pyridoxal
- medicine
- monoglyceride
-
orthotopic
-
galactose-type
- galnac
- selenomethionine
- anandamide
- freundii
-
2-arachidonoyl
-
citrobacter
- alpha-ketobutyrate
- methylselenol
-
meibomian
-
methionine-dependent
- mercaptan
-
beta-lyase
-
5'-phosphate-dependent
-
dc-sign
-
s-substituted
- synthesis
- nutrition
- environmental protection
- analysis
- drug development
Reaction
Synonyms
CalE6, EhMGL1, EhMGL2, fer1MgL2, Fn1419, L-methionase, L-methioninase, L-methionine gamma-lyase, L-methionine gamma-lyase 1, L-methionine-alpha-deamino-gamma-mercaptomethane lyase, L-methionine-alpha-deamino-gamma-mercaptomethane-lyase, L-methionine-gamma-lyase, lyase, methionine, MdeA, MegL, METase, methioninase, methionine alpha,gamma-lyase, methionine dethiomethylase, methionine gamma-lyase, methionine lyase, methionine-gamma-lyase, MGL, MGL1, MGL2, rMETase, sav7062, TvMGL1, TvMGL2, YtjE
ECTree
Advanced search results
Application
Application on EC 4.4.1.11 - methionine gamma-lyase
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
analysis
drug development
environmental protection
-
enzyme is not an important source of volatile methanethiol
medicine
nutrition
synthesis
-
presence of a hybrid plasmid in Escherichia coli K12 containing the enzyme gene leads to a decrease in efficiciency of EcoKI restriction
-
the enzyme can be used for detection of S-adenosyl-L-homocysteine hydrolase activity and inhibition in a simple and robust fluorogenic enzymatic assay, method development, overview
analysis
assay for methionine gamma-lyase-catalyzed gamma-elimination reactions of L-methionine and its analogues with 2-oxobutanoate as product. The assay employs UV-Vis spectrophotometry to continuously monitor the rate of formation of 2-oxobutanoate by its absorbance at 315 nm
analysis
-
the enzyme can be used for detection of S-adenosyl-L-homocysteine hydrolase activity and inhibition in a simple and robust fluorogenic enzymatic assay, method development, overview
-
-
endotoxins cause fever in humans and must be eliminated from biopharmaceuticals intended for parenteral administration which are produced by Escherichia coli. Endotoxins can be drastically removed by anion-exchange column chromatography. Thus, the combination of crystallization and anion-exchange column chromatography is suitable for purification of the enzyme
drug development
-
methyl mercaptan may not only cause oral malodour but also play an important role in the pathogenicity of Treptonema denticola. The enzyme may be an exploitable target for novel chemotherapeutic drugs. An inhibitor of METase may represent a new class of compounds with the potential for preventing and treating oral malodor
medicine
-
rMETase is an enzyme active in preclinical mouse models of human cancer
medicine
-
PEG treated METase is a potential anticancer agent that can deplete L-methionine from plasma. DTT-treated PEG-METase can be produced on a large scale in sufficient quality for therapeutic use
medicine
-
recombinant METase targets the elevated methionine dependence of tumor cells and arrests their growth as well as makes tumors more sensitive to standard chemotherapy agents. The combination of methoxypolyethylene glycol succinimidyl glutarate 5000 recombinant METase treatment with pyridoxal-5'-phosphate infusion suggests an effective clinical strategy for long-term methionine depletion to arrest cancer growth
medicine
-
combined treatment of B16-F10 melanoma cells with selenomethionine and L-methionine gamma-lyase added to culture medium decreases expression of integrins alpha4, beta1, alphany and beta3 and inhibits melanoa-extracellular matrix adhesion. Caspase-mediated apoptosis is induced following loss of cell adherence
medicine
-
wild-type p53-expressing LNCaP human prostate cancer cells are more sensitive to cotreatment with selenomethionine and methionine gamma-lyase than p53-null PC3 human prostate cancer cells. Selenomethionine and and methionine gamma-lyase co-treatment significantly increases levels of superoxide and apoptosis in LNCaP cells. Cotreatment selenomethionine and methionine gamma-lyase results in increased levels of phosphorylated p53, total p53, Bax, and p21Waf1 proteins. LNCaP cells treated with selenomethionine and methionine gamma-lyase also show p53 translocation to mitochondria, decreased mitochondrial membrane potential, cytochrome c release into the cytosol, and activation of caspase 9. The effects selenomethionine and methionine gamma-lyase are suppressed by pre-treatment with a synthetic superoxide dismutase mimic or by knockdown of p53 via RNA interference
medicine
-
causes adverse reaction in treatment of amoebiasis with trifluormethionine by degradation
medicine
-
enzyme therapy against various types of methionine-dependent tumors
medicine
-
enzyme therapy against various types of methionine-dependent tumors
medicine
-
enzyme therapy against various types of methionine-dependent tumors
medicine
-
enzyme therapy against various types of methionine-dependent tumors
medicine
-
enzyme therapy against various types of methionine-dependent tumors
medicine
-
enzyme therapy against various types of methionine-dependent tumors
medicine
-
enzyme therapy against various types of methionine-dependent tumors
medicine
-
enzyme therapy against various types of methionine-dependent tumors
medicine
-
enzyme therapy against various types of methionine-dependent tumors
medicine
-
enzyme therapy against various types of methionine-dependent tumors
medicine
-
enzyme therapy against various types of methionine-dependent tumors
medicine
Achromobacter starkeyi
-
enzyme therapy against various types of methionine-dependent tumors
medicine
-
enzyme therapy against various types of methionine-dependent tumors
medicine
-
inhibitory effect of fusion protein on an ovaran cancer cell line, fusion protein produces a dose-dependent inhibition of the proliferation of pancreatic cancer cell lines
medicine
-
the enzyme is of interest as an anticancer agent, since the growth of malignant cells of various origins (unlike the growth of normal cells) is accompanied by obligatory methionine utilization, and the enzyme is absent in mammalian cells. IC50 of MGL for several tumor cell cultures, overview
medicine
-
the enzyme is of interest as an anticancer agent, since the growth of malignant cells of various origins (unlike the growth of normal cells) is accompanied by obligatory methionine utilization, and the enzyme is absent in mammalian cells. IC50 of MGL for several tumor cell cultures, overview
medicine
-
the enzyme is of interest as an anticancer agent, since the growth of malignant cells of various origins (unlike the growth of normal cells) is accompanied by obligatory methionine utilization, and the enzyme is absent in mammalian cells. IC50 of MGL for several tumor cell cultures, overview
medicine
encapsulation of enzyme in nanoporous wet silica gels to be delivered at the site of action. Gels exhibit spectroscopic properties very similar to methionine gamma lyase in solution, a higher stability with respect to the soluble enzyme and catalytic activity is 6fold lower than in solution
medicine
mice plasma methionine decreases to undetectable level 10 min after methionine gamma lyase 1000 U/kg injection. The enzyme shows a pharmakokinetic half-life of 0.76 h
medicine
mice plasma methionine decreases to undetectable level 10 min after methionine gamma lyase 1000 U/kg injection. The enzyme shows a pharmakokinetic half-life of 0.91 h
medicine
mice plasma methionine decreases to undetectable level 10 min after methionine gamma lyase 1000 U/kg injection. The enzyme shows a pharmakokinetic half-life of 1.69 h
medicine
mutant V358Y selectively inhibits cancer cell growth with a half-maximal inhibitory concentration almost 2fold lower than the wild type
medicine
-
the enzyme significantly inhibits proliferation of leukemia cell lines and induces cellular apoptosis
medicine
-
mice plasma methionine decreases to undetectable level 10 min after methionine gamma lyase 1000 U/kg injection. The enzyme shows a pharmakokinetic half-life of 0.91 h
-
medicine
-
enzyme therapy against various types of methionine-dependent tumors
-
the enzymatic degradation of L-methionine and subsequent formation of volatile sulfur compounds is believed to be essential for flavour development in cheese. Overproduction of Brevibacterium linens methionine-gamma-lyase in bacteria such as lactic acid bacteria can be a more efficient way to increase cheese flavour of some cheeses, among others, cheddar, than the addition of Brevibacterium linens cells or extracts, which is not successful in enhancing cheese flavour
nutrition
importance in flavor formation during cheese ripening